Farm animals and aquaculture cryopreservation partnership announced
With the aim to jointly commercialise a global cryopreservation offering for farm animals and aquaculture, Vitrafy Life Sciences Limited has announced that it has entered a 12-month Strategic Commercial Agreement with IMV Technologies — a French-based multinational conglomerate with over 500 million animal inseminations annually.
In a statement about the agreement, Vitrafy said the partnership is designed to integrate its next-generation cryopreservation technology with IMV’s globally recognised offering. “This agreement with IMV Technologies represents a significant step in Vitrafy’s commercialisation strategy,” Managing Director and CEO Brent Owens said.
“By partnering with the global leader in animal reproduction, we accelerate the validation and adoption of our cryopreservation technology at scale,” Owens added. “This Agreement creates immediate revenue opportunities but also positions Vitrafy for long-term growth through global market access, while we continue to advance our human health strategy in North America.”
Oliver Kohlhaas, CEO of IMV Technologies, commented: “Vitrafy’s unique nitrogen-free cryopreservation technology has the potential to improve post-thaw cell viability. We are excited to collaborate with Vitrafy to offer even better solutions for our customers.”
Scientists 'reprogram' tumour-supporting immune cells
The approach, by an Australian team, uses lipid nanoparticles to target a type of immune cell...
Existing medicines could help treat deadly childhood dementia
Australian researchers have identified several existing TGA‑approved medicines that could help...
Statins reduce heart attack and stroke risk in older people
It has previously been unclear whether statins were effective in reducing heart attack and stroke...
